DSC Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

DSC Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,000	Closed	-$1.01M	–	90
2018 Q4	$1.01M	Hold	10,000	–	–	0.12%	29
2018 Q3	$1.26M	Hold	10,000	–	–	0.17%	35
2018 Q2	$839K	Buy	10,000 +6,500	+186%	+$476K	0.14%	55
2018 Q1	$215K	Hold	3,500	–	–	0.05%	74
2017 Q4	$204K	Buy	+3,500	New	+$221K	0.12%	68
2016 Q2	–	Sell	-7,000	Closed	-$899K	–	68
2016 Q1	$899K	Hold	7,000	–	–	0.53%	33
2015 Q4	$1.04M	Hold	7,000	–	–	0.55%	30
2015 Q3	$1.16M	Hold	7,000	–	–	0.56%	41
2015 Q2	$1.69M	Hold	7,000	–	–	0.88%	27
2015 Q1	$1.97M	Hold	7,000	–	–	1.05%	27
2014 Q4	$1.09M	Buy	+7,000	New	+$1.29M	0.63%	31

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DSC Advisors's ICPT Position: Q1 2019 in Review

DSC Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 10,000 shares — an estimated $1.01M sold.

DSC Advisors first reported a position in ICPT in Q4 2014 and held it in 11 quarters. The position peaked at $1.97M in Q1 2015. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

DSC Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
DSC Advisors sold 10,000 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.01M.
DSC Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 11 quarters.
DSC Advisors's Intercept Pharmaceuticals, Inc. position peaked at $1.97M in Q1 2015.
202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on DSC Advisors's 13F filing for Q1 2019, filed 15 May 2019.